Reviva announces positive topline results from global pivotal phase 3 recover trial of brilaroxazine in schizophrenia

- successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in positive and negative syndrome scale (panss) total score vs. placebo at week 4, p
RVPH Ratings Summary
RVPH Quant Ranking